Bay­er to pull fol­lic­u­lar lym­phoma drug Aliqopa from US mar­ket in an­oth­er blow to PI3K in­hibitor space

Bay­er said it will vol­un­tar­i­ly with­draw its fol­lic­u­lar lym­phoma drug Aliqopa from the US af­ter a con­fir­ma­to­ry tri­al dis­ap­point­ment, mark­ing the third PI3K in­hibitor to be pulled in re­cent years.

A Bay­er spokesper­son told End­points News in an email that the Phase III CHRONOS-4 tri­al of Aliqopa plus stan­dard im­munother­a­py in pa­tients with re­lapsed in­do­lent non-Hodgkin lym­phoma did not meet its pri­ma­ry end­point, which is list­ed as pro­gres­sion-free sur­vival on Clin­i­cal­Tri­als.gov. Topline da­ta from the con­fir­ma­to­ry study are yet to be pub­lished.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER